High-Speed Multimode Microplate Reader Receives Homogenous Time-Resolved Fluorescence Certification
|
By LabMedica International staff writers Posted on 19 Aug 2015 |

Image: The Synergy Neo2 Multi-Mode Reader recently received Cisbio HTRF certification (Photo courtesy of BioTek Instruments Inc.).
A new high-performance, high-speed microplate reader has received HTRF (homogenous time-resolved fluorescence) accreditation that certifies that it complies with standards for detection set by a major manufacturer of HTRF reagents.
HTRF involves several carefully selected fluorophores. Fluorescence resonance energy transfer (FRET) partners must fulfill multiple compatibility criteria. First, their emission spectra must show non-overlapping regions in order to be able to measure each partner's fluorescence individually. Second, the FRET quantum yield (i.e., its efficacy) must be as high as possible. Third, fluorescence emission must occur within a region of the spectrum remote from that naturally produced by proteins; in other words, a red-shifted emission is theoretically better in order to avoid medium-intrinsic fluorescence. HTRF uses a combination of several fluorophores forming different FRET systems. HTRF's central element, the energy donor, consists of a rare earth complex in which the lanthanide ion (europium or terbium) is tightly embedded in a macrocycle. This very unique type of structure gives HTRF donors their long-lived fluorescence properties, as well as robustness that enables these molecules to be used in most assay conditions.
In order to broaden HTRF readout capabilities for use in the field of life sciences, Cisbio Bioassays (Codolet, France) has initiated partnerships with several detection system manufacturers. This collaboration has led to high standard reader certification, indicated by an HTRF sticker. This label guarantees that the reader meets the physical specifications for optimal HTRF readout.
Cisbio recently added the BioTek (Winooski, VT, USA) Synergy Neo2 Multi-Mode Reader to the list of instruments with HTRF certification.
The Synergy Neo2 Multi-Mode Reader was designed for speed and ultra-high quality performance. It incorporates BioTek's patented Hybrid technology, which combines independent monochromator-based and filter-based optics in the same instrument. Thus, continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to four photomultiplier tubes provide ultra-fast measurements with high quality results.
Complementing its sophisticated optic systems, the Synergy Neo2 boasts advanced environment controls, including CO2/O2 control and incubation up to 65 degrees Celsius. Variable shaking supports live cell assays, while cell-based detection is optimized with direct bottom illumination.
The instrument package is powered by BioTek's Gen5 Data Analysis Software and has been configured to integrate seamlessly with the optional BioStackNeo plate stacker, which was designed specifically for use with the Synergy Neo2.
Gary Barush, director of marketing and sales at BioTek, said, “For years BioTek has led the evolution of multimode detection. We are proud to introduce this top-of-the-line reader which combines best in class performance in all modes with the speed that customers demand. In addition to being optimized for biochemical assay performance, Synergy Neo2 provides unsurpassed results for cell based assay detection, while its modular configuration makes this new level of performance accessible for many budgets."
Related Links:
Cisbio Bioassays
BioTek
HTRF involves several carefully selected fluorophores. Fluorescence resonance energy transfer (FRET) partners must fulfill multiple compatibility criteria. First, their emission spectra must show non-overlapping regions in order to be able to measure each partner's fluorescence individually. Second, the FRET quantum yield (i.e., its efficacy) must be as high as possible. Third, fluorescence emission must occur within a region of the spectrum remote from that naturally produced by proteins; in other words, a red-shifted emission is theoretically better in order to avoid medium-intrinsic fluorescence. HTRF uses a combination of several fluorophores forming different FRET systems. HTRF's central element, the energy donor, consists of a rare earth complex in which the lanthanide ion (europium or terbium) is tightly embedded in a macrocycle. This very unique type of structure gives HTRF donors their long-lived fluorescence properties, as well as robustness that enables these molecules to be used in most assay conditions.
In order to broaden HTRF readout capabilities for use in the field of life sciences, Cisbio Bioassays (Codolet, France) has initiated partnerships with several detection system manufacturers. This collaboration has led to high standard reader certification, indicated by an HTRF sticker. This label guarantees that the reader meets the physical specifications for optimal HTRF readout.
Cisbio recently added the BioTek (Winooski, VT, USA) Synergy Neo2 Multi-Mode Reader to the list of instruments with HTRF certification.
The Synergy Neo2 Multi-Mode Reader was designed for speed and ultra-high quality performance. It incorporates BioTek's patented Hybrid technology, which combines independent monochromator-based and filter-based optics in the same instrument. Thus, continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to four photomultiplier tubes provide ultra-fast measurements with high quality results.
Complementing its sophisticated optic systems, the Synergy Neo2 boasts advanced environment controls, including CO2/O2 control and incubation up to 65 degrees Celsius. Variable shaking supports live cell assays, while cell-based detection is optimized with direct bottom illumination.
The instrument package is powered by BioTek's Gen5 Data Analysis Software and has been configured to integrate seamlessly with the optional BioStackNeo plate stacker, which was designed specifically for use with the Synergy Neo2.
Gary Barush, director of marketing and sales at BioTek, said, “For years BioTek has led the evolution of multimode detection. We are proud to introduce this top-of-the-line reader which combines best in class performance in all modes with the speed that customers demand. In addition to being optimized for biochemical assay performance, Synergy Neo2 provides unsurpassed results for cell based assay detection, while its modular configuration makes this new level of performance accessible for many budgets."
Related Links:
Cisbio Bioassays
BioTek
Latest Technology News
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
- Aptamer Biosensor Technology to Transform Virus Detection
- AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
- AI-Generated Sensors Open New Paths for Early Cancer Detection
- Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
- AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
- Diagnostic Chip Monitors Chemotherapy Effectiveness for Brain Cancer
- Machine Learning Models Diagnose ALS Earlier Through Blood Biomarkers
- Artificial Intelligence Model Could Accelerate Rare Disease Diagnosis
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







